Verzögert
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
2,54 USD | +0,79 % |
|
+4,36 % | +96,48 % |
Kurzporträt
Mitarbeiterzahl: 28
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 04.01.16 |
Preston Klassen
PSD | President | 55 | 22.06.23 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 30.08.19 |
Rekha Garg
CTO | Chief Tech/Sci/R&D Officer | - | 29.11.22 |
Chief Tech/Sci/R&D Officer | - | 29.11.22 | |
Amin Kamel
PRN | Corporate Officer/Principal | - | 02.06.22 |
Daniel Penksa
AUD | Comptroller/Controller/Auditor | 39 | 01.06.15 |
Christopher Aker
LAW | General Counsel | 63 | 19.05.11 |
Brian K. Campion
PRN | Corporate Officer/Principal | - | 01.07.20 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 01.06.17 |
David Baltimore
BRD | Director/Board Member | 86 | 01.01.09 |
Director/Board Member | 75 | 01.04.13 | |
Chairman | 75 | 01.01.08 | |
Jake Nunn
BRD | Director/Board Member | 53 | 11.06.19 |
Alice Huang
BRD | Director/Board Member | 85 | 26.01.21 |
Hugh Rosen
BRD | Director/Board Member | 65 | 02.06.16 |
Joseph Hagan
CEO | Chief Executive Officer | 55 | 04.01.16 |
Preston Klassen
PSD | President | 55 | 22.06.23 |
Kathryn Collier
BRD | Director/Board Member | 56 | 17.04.18 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 0 | 3 725 720 | 0 | 0 | 95,99 % |
Aktie B | 0 | 258 707 | 0 | 0 | |
Aktie C | 0 | 1 330 832 | 0 | 0 | |
Aktie D | 1 | 65 465 876 | 64 363 679 ( 98,32 %) | 0 | |
Aktie E | 0 | 256 700 | 0 | 0 |
Unternehmenskontakt
Regulus Therapeutics, Inc.
4224 Campus Point Court Suite 210
92121, San Diego
+858 202 6300
http://www.regulusrx.com![Straße Regulus Therapeutics Inc.(RGLS)](https://cdn.zonebourse.com/static/address/46475580.png)
Sektor
![Analystenschätzungen](/images/consensus_flch.gif)
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+96,48 % | 165 Mio. | |
+15,48 % | 122 Mrd. | |
+20,47 % | 113 Mrd. | |
+8,24 % | 22,84 Mrd. | |
-19,85 % | 20,72 Mrd. | |
-16,19 % | 16,51 Mrd. | |
-13,66 % | 16,39 Mrd. | |
-44,35 % | 15,83 Mrd. | |
+2,76 % | 13,49 Mrd. | |
+67,00 % | 11,67 Mrd. |
- Börse
- Aktien
- A3DNZ4 Aktie
- Unternehmen Regulus Therapeutics Inc.